key: cord-0822321-6orrgcbk
authors: Ter-Ovanesyan, D.; Gilboa, T.; Lazarovits, R.; Rosenthal, A.; Yu, X. G.; Li, J. Z.; Church, G. M.; Walt, D. R.
title: Ultrasensitive measurement of both SARS-CoV2 RNA and serology from saliva
date: 2021-01-26
journal: nan
DOI: 10.1101/2021.01.25.21249679
sha: 7b100fb623486684d6714eaada2028be9544f35e
doc_id: 822321
cord_uid: 6orrgcbk

Tests for COVID-19 generally measure SARS-CoV2 viral RNA from nasal swabs or antibodies against the virus from blood. It has been shown, however, that both viral particles and antibodies against those particles are present in saliva, which is more accessible than both swabs and blood. We present methods for highly sensitive measurements of both viral RNA and serology from the same saliva sample. We developed an efficient saliva RNA extraction method and combined it with an ultrasensitive serology test based on Single Molecule Array (Simoa) technology. We apply our test to the saliva of patients who presented to the hospital with COVID-19 symptoms, some of whom tested positive with a conventional RT-qPCR nasopharyngeal swab test. We demonstrate that combining viral RNA detection by RT-qPCR with serology identifies more patients as infected than either method alone. Our results suggest the utility of combining viral RNA and serology testing from saliva, a single easily accessible biofluid.

The two main tests for SARS-CoV2 infection are molecular tests to detect the presence of the virus (RNA or antigen) and serological tests to detect the presence of antibodies against the virus 1-6 . Both tests have advantages and disadvantages. RT-qPCR, the main diagnostic test and current gold standard, is a sensitive method for measuring the presence of viral RNA, usually performed from nasopharyngeal (NP) or anterior nasal swabs 1-3 . However, it has been shown that not all patients who are infected with SARS-CoV2 test positive for viral RNA 1,2,5,7-9 .

There are several potential reasons for this: low viral load, variability in swabbing, or late swab collection relative to the time of infection 2, 5 . The time at which the swab is performed is important because, after initial infection, levels of virus sharply rise and then drop, providing a relatively narrow window at which viral RNA is present 1,5,6,10-18 . Serology tests detect antibodies that develop against the virus during infection 1, 6 . These antibodies remain stable for at least several months, widening the time window of testing for SARS-CoV2 infection [19] [20] [21] . Combining RNA detection with serology testing has the potential to increase the sensitivity of RT-qPCR alone 6, 12, 20, [22] [23] [24] [25] [26] by reducing false negatives in RT-qPCR.

RT-qPCR tests for SARS-CoV2 mostly analyze RNA from nasal swabs, while serology tests are generally performed using blood 1, 22, [27] [28] [29] . However, studies have shown that both SARS-CoV2 viral RNA 12,30-33 and antibodies 19, 30, 34 against the virus are present in saliva. Since saliva is easier to collect than either swabs or blood, its accessibility makes it an ideal biofluid for widespread diagnostic use. Research is still ongoing regarding how well saliva correlates to different types of swabs in terms of sensitivity of viral RNA detection [30] [31] [32] 35, 36 . This will depend largely on several factors such as patient selection, sample collection, and RNA extraction methodology. Nonetheless, it is clear that SARS-CoV2 viral RNA can be readily detected in saliva 12, [30] [31] [32] . Similarly, previous studies have shown a strong correlation between antibodies against SARS-CoV2 in blood and saliva 19, 30, 34, [37] [38] [39] .

Although RT-qPCR is highly sensitive, there is great variability in the RNA extraction efficiency, which is generally performed using commercial kits. These kits have advantages in terms of ease, but are prone to supply chain limitations 40 . Furthermore, using kits may lead to incompatibilities with upstream or downstream steps since the components are unknown to the user. Lastly, kits are not optimized for specific biofluids such as saliva, leading to potentially low RNA recovery. Serology testing in saliva also presents challenges; namely, that concentrations of antibodies in saliva are much lower than they are in blood 19, 30, 34 and that different isotypes may be present in the different fluids.

We set out to develop a highly sensitive test to detect both viral RNA and antibodies against the virus from the same saliva sample. We developed an optimized RNA extraction protocol that is highly efficient for saliva. We also adapted a Single Molecule Array 41 (Simoa)based ultrasensitive serology test we previously developed for detecting SARS-CoV2 antibodies in blood for use in saliva 7, 42 . Combining our RNA extraction protocol for RT-qPCR with this ultrasensitive serology test, we are able to better classify COVID-19 patients as being actively or previously infected with SARS-CoV2, demonstrating the utility of this approach for accurate diagnosis of COVID19.

In order to develop a highly sensitive test for both SARS-CoV2 RNA and serology using saliva (schematically presented in Figure 1 ), we first optimized the RNA extraction. We developed two versions: a low-volume version (30μL saliva) that can be performed in a 96-well PCR plate and a high-volume version (300μL saliva) that can be performed in a deep-well plate.

We started with a general method based on binding nucleic acids to carboxylated paramagnetic beads in the presence of a guanidinium thiocyanate lysis buffer (Figure 2a) , and optimized each step of the protocol using saliva samples. To evaluate our extraction method, we spiked in known amounts of synthetic SARS-CoV2 RNA or heat-inactivated SARS-CoV2 viral particles into PBS or human saliva and then quantified recovery after RNA extraction by RT-qPCR.

( Figure 2a, Supplementary Figure 1 ). We tested a large number of parameters using this approach until we arrived at a protocol that consistently resulted in 50-100% recovery in 30μL of saliva ( Figure 2b ). To maximize sensitivity, we opted to use more saliva (300μL) in a deep-well plate format. However, as it is difficult to elute into a small volume using a deep well plate, we included a transfer step in our protocol where we transfer the beads (during a 70% ethanol wash step) from a deep-well plate to a PCR plate, allowing us to elute the RNA in only 10μL

To see how our protocol compares to a commonly used commercial kit, we performed a head-to-head comparison with the ThermoFisher Scientific MagMAX Viral/Pathogen Nucleic Acid Isolation kit. We first extracted RNA from equal volumes of saliva spiked with viral particles and eluted the captured RNA into equal volumes (Figure 2c ). In this comparison, we found that our custom protocol had more than twice the recovery of MagMAX. We also compared our protocol to MagMAX using the maximum input volume and minimum elution volumes for both protocols using saliva with the same concentration of viral particles. In this case, our protocol recovered 16x more RNA (Figure 2d ). We then compared our protocol to three recently . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249679 doi: medRxiv preprint developed protocols for measuring RNA from saliva without purification. These protocols, SalivaDirect 43 , TCEP inactivation 44 , and 95°C heating 45 , all use a small volume of saliva (<10μL) since the final volume of RT-qPCR reactions is usually 20μL. We compared our high-volume RNA extraction to these three protocols using saliva containing the same concentration of viral particles. We found that we detected significantly more RNA in extraction-based protocols, largely due to the ability to use larger volumes of saliva ( Figure 2d ).

After validation of our RNA extraction protocol, we turned to combining RNA detection with serology in clinical saliva samples from COVID-19 patients. We have previously developed Single Molecule Array (Simoa) based ultrasensitive profiling of IgG, IgM, and IgA antibodies against SARS-CoV2 nucleocapsid (N), spike (S), S1, and RBD protein targets in blood 7 . Our assay employs a bead-based, digital ELISA for high-throughput, automated ultrasensitive detection of antibodies in small volumes. Using only 40μL of saliva per sample (10μL for serology and 30μL for RNA), we characterized 12 antibody interactions and quantified SARS-CoV2 RNA across 18 saliva samples. We tested two pre-pandemic saliva samples from healthy individuals, and 16 samples from symptomatic individuals who visited the MGH Respiratory Infection Clinic during the pandemic (see SI Table S1 for clinical characteristics summary). The patients were all tested by RT-qPCR from NP swab samples upon arrival to the clinic and saliva was collected on the same day.

Combined measurement of SARS-CoV2 RNA and IgG, IgM and IgA levels against S1 ( Figure 3a ) revealed that five patients were positive for either RNA, serology, or both, in saliva compared to three patients by NP RT-qPCR alone. Two patients with positive serology in saliva but negative RT-qPCR (in both NP swabs and saliva) displayed severe respiratory illness, and thus likely received false negative RT-qPCR results. RNA was detected in saliva for two of the three patients with positive NP swabs. For the patient with RNA detected in the NP swab but not saliva, antibody levels were above the threshold for IgA and IgM against S1. Since our previous work showed that IgA -S1 displayed the best separation between positives and controls, this sample would be classified as positive in our serological assay. We also measured saliva from a subset of the patients at six late time points (>9 days after the first positive PCR). We found no RNA was detected but antibody levels were high for most of the immunoglobulin subtypes we measured, as expected ( Figure 3b) . Finally, to see if we could achieve multiplexed detection of viral RNA and serology on the same platform from one sample, we developed a Simoa assay for the direct detection of SARS-CoV2 RNA. Although we found this assay to be less sensitive than RT-qPCR, the Simoa assay detects RNA without amplification. We combined this assay . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249679 doi: medRxiv preprint with our serology assay to detect RNA and antibodies spiked into saliva samples (SI Figure S3 , Table S2 ), demonstrating multiplexed detection of RNA and serology on the Simoa platform.

SARS-CoV2 infection is currently diagnosed with RT-qPCR from NP swabs and the immune response is monitored using serology tests from blood or plasma samples 1, 3, 4 . Several studies have shown that saliva is suitable for both SARS-CoV2 viral RNA detection and serology measurements, but these measurements have not been made together using the same sample. In this study, we combined RT-qPCR with serology measurements on a small number of symptomatic COVID-19 patient saliva samples. We demonstrate that combining these measurements identifies SARS-CoV2 infection in patients that RT-qPCR alone misses, providing information that can help guide clinical decision making. This is particularly important in patients who present to the hospital with COVID-19 symptoms but have negative RT-qPCR results despite having been infected with SARS-CoV2 (for example because the immune system has already cleared the virus).

To maximize sensitivity of RNA detection, we developed and optimized a high-efficiency saliva RNA extraction protocol without the use of kits. We found our protocol yields much higher levels of RNA from saliva than a widely-used commercial isolation kit when performed manually.

We also directly compared our RNA extraction method to several recently published noextraction methods for SARS-CoV2 detection by RT-qPCR in saliva. Although these methods greatly increase ease and throughput of RT-qPCR testing, this comes at a cost of sensitivity.

Our high-volume RNA extraction protocol allows for a 30-fold concentration of the saliva sample in addition to the inactivation and removal of enzymatic inhibitors present in saliva. In a comparison utilizing saliva spiked with virus, our high-volume RNA extraction protocol led to the detection of at least 56 times more viral RNA than the use of inactivated saliva as input.

To maximize the sensitivity of our serology measurements, we employed serology assays that we recently developed using Single Molecule Array (Simoa) technology 7 . The high sensitivity of these assays is particularly advantageous in saliva, where antibody levels are known to be low 19, 30, 34 . We have also demonstrated that serology measurements can be combined with direct, amplification-free detection of RNA in saliva samples. We envision that the sensitivity of the RNA assay can be further improved, for example, by adding Cas13a-based detection 49 . Future studies may also incorporate additional protein biomarkers in saliva to measure inflammation (cytokines, etc.) or other aspects of host response to increase the utility of multiplexed saliva diagnostics for COVID-19.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. Three volumes of isopropyl alcohol (Millipore Sigma) were added to each reaction, and the samples were mixed well by pipetting up and down ten times. Samples were incubated for five minutes at room temperature to allow RNA to bind to beads, and then placed on a magnet.

When solution cleared (approximately 2 minutes for small-volume extraction or 15-20 minutes for large-volume extraction), with the plate still on the magnet, supernatant was removed. When using low-volume (200μL) plates: beads were washed twice with 150μL of 70% ethanol.

Ensuring that all of the ethanol is removed, RNA was then eluted using 10μL of nuclease-free water. When using high-volume (deep-well) plates: 150μL of 70% ethanol was added and beads were resuspended in 70% ethanol off of the magnet and transferred to a PCR plate. The . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249679 doi: medRxiv preprint PCR plate was then placed on magnet and supernatant was removed. Another 150μL of 70% ethanol was added to the deep-well plate to get any residual beads and transferred to beads on the PCR plate. One last 70% ethanol wash step was then performed on the PCR plate and all 70% ethanol removed. RNA was eluted using either 20μL (for recovery experiments) or 10μL (for comparison to other methods) of nuclease-free water.

For all comparison experiments, pooled human saliva spiked in with heat-inactivated virus at 50 particles/μL was used. For the comparison of the custom protocol to the commercial kit, ThermoFisher Scientific MagMAX Viral/Pathogen Nucleic Acid Isolation was used according to manufacturer's protocol with either 200μL input volume or 400μL input volume and 50μL elution volume. For the comparison to the no-extraction protocols, saliva with virus was transferred to PCR strip tubes for inactivation. For the 95°C protocol, saliva was heated at 95°C for 5 minutes.

For the TCEP protocol, Tris(2-carboxyethyl)phosphine hydrochloride (Millipore Sigma) was dissolved in water, EDTA was added to a final concentration of 0.1M, and NaOH was added until the TCEP solution reached a pH of 8. This TCEP solution was added 1:100 to saliva and heated at 95°C for 5 minutes. For the SalivaDirect Proteinase K protocol, 50μL saliva was added to 6.25μL of Proteinase K, Molecular Biology Grade (New England Biolabs). The tube was then vortexed at 3200 RPM for 1 minute and heated at 95°C for 5 minutes. For all noextraction methods, 8.2μL of inactivated saliva was used as input into the RT-qPCR.

Viral RNA was quantified using Luna Universal Probe One-Step RT-qPCR kit (New England Biolabs) according to the manufacturer's protocol in a CFX96 Real-Time Detection System (Bio-Rad). All RT-qPCR reactions were performed using CDC N1 primers 50 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249679 doi: medRxiv preprint in-plate control (ex. 10,000 viral particles) were calculated using the equation:

SARS-CoV2 serological measurements were performed as previously described 7 . The saliva samples were 100-fold diluted in ThermoFisher Scientific StartingBlock T20 Blocking Buffer (PBS) with 1X Halt Protease Inhibitor Cocktail (ThermoFisher Scientific) with EDTA. The Simoa assays were performed on the automated HD-X Analyzer (Quanterix). IgG, IgA and IgM against RBD, S1, spike, and nucleocapsid were measured in duplicate and the average AEB (average enzyme per bead) for each interaction was calculated.

A Simoa assay against SARS-CoV2 RNA was developed as described in detail in the Supplementary Information. Briefly, LNA capture probes were coupled to dye-encoded carboxylmodified paramagnetic beads using EDC and Sulfo-NHS 48 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. PBS or saliva (30μL for low volume or 300μL for high volume) were spiked with 10,000 copies of synthetic SARS-CoV2 RNA (RNA). Our custom RNA extraction protocol was performed, and extracted RNA was compared to equivalent input amounts of spiked in RNA using RT-qPCR.

Recovery of RNA is calculated as RNA level of extracted SARS-CoV2 RNA relative to spike in amount. C) Direct comparison of custom protocol with commercial kit using same volume. RNA . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249679 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249679 doi: medRxiv preprint

Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Molecular Diagnosis of COVID-19: Challenges and Research Needs

Towards effective diagnostic assays for COVID-19: a review

Laboratory Diagnosis of COVID-19: Current Issues and Challenges

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Interpreting Diagnostic Tests for SARS-CoV-2

Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19

Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management

Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak

Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review. medRxiv Prepr Serv Heal Sci

Temporal dynamics in viral shedding and transmissibility of COVID-19

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Virological assessment of hospitalized patients with COVID-2019

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (80-)

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Early Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies as a Serologic Marker of Infection in Patients With Coronavirus Disease

Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics

Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A General Perspective

Consistent Detection of 2019 Novel Coronavirus in Saliva

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva

Saliva as a possible tool for the SARS-CoV-2 detection: a review

Evaluation of saliva as an alternative diagnostic specimen source for SARS-CoV-2 detection by RT-dPCR

High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology

Detection of antibodies in saliva--an effective auxiliary method in surveillance of infectious diseases

Salivary biomarkers: toward future clinical and diagnostic utilities

Rapid Scaling Up of Covid-19

Diagnostic Testing in the United States -The NIH RADx Initiative

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease

SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. medRxiv

SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive protocol for sample inactivation and purification

Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR

Simultaneous detection of small molecules, proteins and microRNAs using single molecule arrays

Sequential Protein Capture in Multiplex Single Molecule Arrays: A Strategy for Eliminating Assay Cross-Reactivity

Digital direct detection of microRNAs using single molecule arrays

Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy

CDC. CDC 2019-Novel Coronavirus [2019-NCoV] Real-Time RT-PCR Diagnostic Panel.; 2020

The authors acknowledge funding from the Bill and Melinda Gates Foundation for this work. The